GOOG: $309.30 ▼ -1.22 (-0.39%)MU: $237.50 ▼ -3.64 (-1.51%)AMD: $207.61 ▼ -3.17 (-1.50%)AVGO: $339.86 ▼ -20.07 (-5.58%)LLY: $1,062.71 ▲ 35.20 (3.43%)LRCX: $164.34 ▲ 3.82 (2.38%)AMAT: $261.36 ▲ 2.15 (0.83%)MRK: $100.37 ▲ 0.07 (0.06%)CRM: $254.28 ▼ -7.96 (-3.04%)LIN: $416.97 ▲ 0.73 (0.18%)META: $647.54 ▲ 3.31 (0.51%)NFLX: $93.76 ▼ -1.43 (-1.50%)ORCL: $184.82 ▼ -5.15 (-2.71%)USDEUR: $0.85 ▲ 0.00 (-0.04%)ARGX.BR: $726.60 ▲ 3.00 (0.41%)ASML.AS: $914.00 ▼ -17.00 (-1.83%)AZN.L: $13,564.00 ▼ -48.00 (-0.35%)BARC.L: $454.21 ▼ -0.05 (-0.01%)BBVA.MC: $19.54 ▼ -0.02 (-0.10%)ENR.DE: $118.60 ▼ -0.95 (-0.79%)MC.PA: $636.00 ▲ 9.90 (1.58%)RWE.DE: $43.90 ▲ 0.28 (0.64%)STAN.L: $1,751.50 ▼ -9.00 (-0.51%)UCB.BR: $238.60 ▲ 0.50 (0.21%)XAUUSD: $4,276.97 ▼ -27.95 (-0.65%)IEF: $96.29 ▲ 0.10 (0.10%)TLT: $87.41 ▲ 0.06 (0.07%)CAT: $590.02 ▼ -7.88 (-1.32%)TMO: $575.78 ▲ 3.50 (0.61%)AIR.PA: $192.38 ▼ -3.74 (-1.91%)BATS.L: $4,312.78 ▲ 15.78 (0.37%)BP.L: $433.50 ▼ -3.95 (-0.90%)CFR.SW: $168.85 ▲ 1.00 (0.60%)EL.PA: $281.60 ▼ -0.90 (-0.32%)GSK.L: $1,848.00 ▲ 14.50 (0.79%)LLOY.L: $94.50 ▼ -0.64 (-0.67%)RIO.L: $5,663.00 ▲ 31.00 (0.55%)ROG.SW: $323.10 ▲ 1.20 (0.37%)INTC: $37.51 ▼ -0.30 (-0.79%)AAPL: $274.20 ▼ -4.09 (-1.47%)JNJ: $214.18 ▲ 2.60 (1.23%)BAYN.DE: $35.99 ▲ 0.12 (0.32%)GLEN.L: $379.15 ▼ -1.65 (-0.43%)SAN.MC: $9.90 ▲ 0.03 (0.31%)STX: $285.44 ▼ -2.20 (-0.76%)WDC: $171.99 ▼ -4.35 (-2.47%)AMZN: $222.53 ▼ -3.66 (-1.62%)MSFT: $474.75 ▼ -3.78 (-0.79%)NVDA: $176.12 ▲ 1.10 (0.63%)ARKK: $79.21 ▼ -1.18 (-1.47%)IBB: $169.42 ▼ -0.02 (-0.01%)IGV: $105.41 ▼ -2.57 (-2.38%)RSP: $193.68 ▲ 0.27 (0.14%)SOXX: $298.04 ▼ -1.44 (-0.48%)XBI: $122.84 ▼ -0.29 (-0.24%)XLY: $121.73 ▲ 1.03 (0.85%)WBD: $29.74 ▼ -0.24 (-0.80%)GS: $889.59 ▲ 1.63 (0.18%)WMT: $116.81 ▲ 0.11 (0.09%)HSBA.L: $1,114.60 ▼ -10.20 (-0.91%)INGA.AS: $23.39 ▲ 0.06 (0.26%)UBSG.SW: $34.87 ▲ 0.71 (2.08%)ULVR.L: $4,837.50 ▼ -7.50 (-0.15%)

Company Details

Autolus Therapeutics plc

AUTL - NASDAQ

Identifiants & Marche

Ticker AUTL
ISIN US05280R1005
CIK 0001730463
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays GB
Siege N/A
Fondee N/A
Site Web Lien

Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Voir l'evolution du cours Retour